North America Epigenetics Market

North America Epigenetics Market Size (2023 to 2028)

The North American Epigenetics Market size was estimated to be USD 233.37 million in 2023 and is predicted to reach USD 426.18 million by 2028, growing at a CAGR of 12.8 % during the forecast period.

Rising cancer prevalence, and increased research and development activities, and growing applications in Epigenetics are majorly promoting the growth rate of the North American epigenetics market.  Also, the financing for epigenetics research and developing uses of epigenetics in non-oncology illnesses contribute to the market growth. Moreover, Cancer is the second most common cause of mortality in the United States, accounting for almost one out of every four fatalities. 

In the coming years, the expanding application areas of epigenetics in non-oncology illnesses, customized medicine, and target treatment are likely to create potential possibilities for market participants. Also, increase in the risk of cardiovascular diseases and an increase in the investments in research and development practices. 

The market expansion is hampered by the high cost of instruments, a scarcity of skilled specialists. Also, the scarcity and lack of financing plans and awareness about epigenetics impede market growth.

Impact of COVID-19 on the North American epigenetics market:

COVID-19 illness is shown to be the most severe in those aged 65 and up who have pre-existing chronic diseases. This is nonexperimental observational research that looks at the results of COVID-19 in different patient groups. 

In the COVID-19 pandemic, epigenetics has played a critical role in the inflexibility of symptoms. Precision medicine is committed to a large rise in protecting the epigenetic variability in SARS-Cov-2 infection, with efforts focused on recognizing and promoting efficient pharma strategies.

The symptoms and severity of COVID-19 disease are both influenced by epigenetic mechanisms. The structure and anatomy of SARS-Cov-2, as well as other illnesses, have been identified. Researchers and physicians must incorporate epigenetic processes to create reliable prescriptions for global well-being to succeed in illness prevention in the long run.

This research report on the North America Epigenetics Market has been segmented & sub-segmented into the following categories:

By Product: 

• Enzymes
• Instruments & Consumable
• KITS
• Reagents

By Research Area: 

• Developmental Biology
• Oncology
• Drug Delivery

By Enzymes: 

• DNA-Modifying Enzymes
• Protein-Modifying Enzymes
• RNA-Modifying Enzymes

By Instruments & Consumables: 

• Mass Spectrometers
• Next-Generation Sequencers
• qPCR
• Sonicators

By KITS:

• Bisulfite Conversion KITS
• Chip-Sequence KITS
• RNA Sequencing KITS
• Whole-Genome Amplification KITS
• 5-HMC and 5-MC Analysis KITS

By Reagents:

• Antibodies
• Buffers
• Histones
• Magnetic Beads
• Primers

By Country: 

• The U.S.
• Canada
• Rest of North America

Geographically, North America dominated the global market in 2022 due to its advanced technology and significant presence.

The U.S. Epigenetics Market is estimated to account for the most significant share in the North American epigenetics market during the forecast period. Y-O-Y growth in cancer incidence is majorly accelerating the epigenetics market in the United States. In addition, enlarging epigenetics applications in non-oncology diseases, personalized medicine, and target therapy are further anticipated to boost the market's growth rate. 

The Canadian epigenetics market is predicted to be another lucrative regional market in the North American market during the forecast period. The increasing obesity population, growing research on oncology diseases, and increasing collaborations between research institutes, biotechnology, and biopharmaceutical companies are estimated to support Canada's market growth. 

KEY MARKET PLAYERS:

A few of the notable companies playing a leading role in the North America epigenetics market are Abcam plc., Illumina, Inc., QIAGEN N.V., Merck & Co., New England Biolabs, Inc., Sigma-Aldrich Corporation, Thermo Fisher Scientific, Inc., Active Motif, Diagenode, Inc., and Zymo Research Corporation.